
Sean Mcgarry
Examiner (ID: 6820, Phone: (571)272-0761 , Office: P/1674 )
| Most Active Art Unit | 1635 |
| Art Unit(s) | 1635, 1674, 1621, 1809, 1624, 1805 |
| Total Applications | 1927 |
| Issued Applications | 1068 |
| Pending Applications | 344 |
| Abandoned Applications | 554 |
Applications
| Application number | Title of the application | Filing Date | Status |
|---|---|---|---|
Array
(
[id] => 18504855
[patent_doc_number] => 11702660
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2023-07-18
[patent_title] => Modulation of gene expression and screening for deregulated protein expression
[patent_app_type] => utility
[patent_app_number] => 17/159881
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 31
[patent_figures_cnt] => 69
[patent_no_of_words] => 37902
[patent_no_of_claims] => 47
[patent_no_of_ind_claims] => 3
[patent_words_short_claim] => 86
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159881
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159881 | Modulation of gene expression and screening for deregulated protein expression | Jan 26, 2021 | Issued |
Array
(
[id] => 20115023
[patent_doc_number] => 12364707
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2025-07-22
[patent_title] => Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation
[patent_app_type] => utility
[patent_app_number] => 17/159288
[patent_app_country] => US
[patent_app_date] => 2021-01-27
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 18
[patent_figures_cnt] => 38
[patent_no_of_words] => 6781
[patent_no_of_claims] => 20
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 72
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17159288
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/159288 | Manipulation of eIF3 to modulate repeat associated non-ATG (RAN) translation | Jan 26, 2021 | Issued |
Array
(
[id] => 17119830
[patent_doc_number] => 11130953
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2021-09-28
[patent_title] => Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof
[patent_app_type] => utility
[patent_app_number] => 17/158375
[patent_app_country] => US
[patent_app_date] => 2021-01-26
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 7
[patent_figures_cnt] => 12
[patent_no_of_words] => 54066
[patent_no_of_claims] => 30
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 112
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17158375
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/158375 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | Jan 25, 2021 | Issued |
Array
(
[id] => 17198728
[patent_doc_number] => 20210338822
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-11-04
[patent_title] => THERAPEUTIC EXOSOMES AND METHOD OF PRODUCING THEM
[patent_app_type] => utility
[patent_app_number] => 17/156512
[patent_app_country] => US
[patent_app_date] => 2021-01-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 9035
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -30
[patent_words_short_claim] => 14
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17156512
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/156512 | THERAPEUTIC EXOSOMES AND METHOD OF PRODUCING THEM | Jan 21, 2021 | Abandoned |
Array
(
[id] => 19027481
[patent_doc_number] => 11926828
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-03-12
[patent_title] => Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1
[patent_app_type] => utility
[patent_app_number] => 17/150614
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 9
[patent_figures_cnt] => 14
[patent_no_of_words] => 42507
[patent_no_of_claims] => 12
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 159
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150614
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150614 | Methods for treating aging and skin disorders using nucleic acids targeting TYR or MMP1 | Jan 14, 2021 | Issued |
Array
(
[id] => 19242179
[patent_doc_number] => 12012601
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-06-18
[patent_title] => Combination therapy with liposomal antisense oligonucleotides
[patent_app_type] => utility
[patent_app_number] => 17/150151
[patent_app_country] => US
[patent_app_date] => 2021-01-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 10
[patent_figures_cnt] => 17
[patent_no_of_words] => 30294
[patent_no_of_claims] => 19
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 55
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17150151
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/150151 | Combination therapy with liposomal antisense oligonucleotides | Jan 14, 2021 | Issued |
Array
(
[id] => 18230356
[patent_doc_number] => 20230069350
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-03-02
[patent_title] => METHODS AND COMPOSITIONS RELATING TO PROLONGED INFLAMMATORY INHIBITION AND/OR PROLONGED TREATMENT OF SPINAL PAIN BY CHIMERA DECOY
[patent_app_type] => utility
[patent_app_number] => 17/793377
[patent_app_country] => US
[patent_app_date] => 2021-01-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18023
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -14
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17793377
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/793377 | METHODS AND COMPOSITIONS RELATING TO PROLONGED INFLAMMATORY INHIBITION AND/OR PROLONGED TREATMENT OF SPINAL PAIN BY CHIMERA DECOY | Jan 13, 2021 | Pending |
Array
(
[id] => 19505164
[patent_doc_number] => 12116576
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-10-15
[patent_title] => Oligonucleotides for modulating SCN9A expression
[patent_app_type] => utility
[patent_app_number] => 17/130451
[patent_app_country] => US
[patent_app_date] => 2020-12-22
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 37245
[patent_no_of_claims] => 16
[patent_no_of_ind_claims] => 1
[patent_words_short_claim] => 128
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17130451
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/130451 | Oligonucleotides for modulating SCN9A expression | Dec 21, 2020 | Issued |
Array
(
[id] => 16900743
[patent_doc_number] => 20210179659
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-17
[patent_title] => ANTISENSE NUCLEIC ACIDS
[patent_app_type] => utility
[patent_app_number] => 17/126366
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 16573
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -12
[patent_words_short_claim] => 225
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126366
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/126366 | ANTISENSE NUCLEIC ACIDS | Dec 17, 2020 | Abandoned |
Array
(
[id] => 16916293
[patent_doc_number] => 20210189385
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-24
[patent_title] => CLOSED LOOP CONTINUOUS APTAMER DEVELOPMENT SYSTEM
[patent_app_type] => utility
[patent_app_number] => 17/126842
[patent_app_country] => US
[patent_app_date] => 2020-12-18
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 10313
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -17
[patent_words_short_claim] => 130
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17126842
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/126842 | Closed loop continuous aptamer development system | Dec 17, 2020 | Issued |
Array
(
[id] => 18071587
[patent_doc_number] => 11530411
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2022-12-20
[patent_title] => Methods for reducing LRRK2 expression
[patent_app_type] => utility
[patent_app_number] => 17/125738
[patent_app_country] => US
[patent_app_date] => 2020-12-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14899
[patent_no_of_claims] => 25
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 110
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17125738
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/125738 | Methods for reducing LRRK2 expression | Dec 16, 2020 | Issued |
Array
(
[id] => 17657421
[patent_doc_number] => 20220177886
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-06-09
[patent_title] => APTAMERS AGAINST CLOSTRIDIUM DIFFICILE, COMPOSITIONS COMPRISING APTAMERS AGAINST CLOSTRIDIUM DIFFICILE AND METHODS OF USING THE SAME
[patent_app_type] => utility
[patent_app_number] => 17/111067
[patent_app_country] => US
[patent_app_date] => 2020-12-03
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 52220
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -33
[patent_words_short_claim] => 28
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17111067
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/111067 | Aptamers against | Dec 2, 2020 | Issued |
Array
(
[id] => 17124337
[patent_doc_number] => 20210299105
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-09-30
[patent_title] => SELECTIVE INHIBITION OF T FOLLICULAR HELPER CELLS FOR TREATMENT OF AUTOIMMUNE DISORDERS
[patent_app_type] => utility
[patent_app_number] => 17/110023
[patent_app_country] => US
[patent_app_date] => 2020-12-02
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 23223
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -20
[patent_words_short_claim] => 43
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17110023
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/110023 | Selective inhibition of T Follicular Helper cells for treatment of autoimmune disorders | Dec 1, 2020 | Issued |
Array
(
[id] => 19166004
[patent_doc_number] => 11981894
[patent_country] => US
[patent_kind] => B2
[patent_issue_date] => 2024-05-14
[patent_title] => Antisense nucleic acids
[patent_app_type] => utility
[patent_app_number] => 16/950449
[patent_app_country] => US
[patent_app_date] => 2020-11-17
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 13
[patent_figures_cnt] => 25
[patent_no_of_words] => 14724
[patent_no_of_claims] => 24
[patent_no_of_ind_claims] => 2
[patent_words_short_claim] => 92
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => patent
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 16950449
[rel_patent_id] =>[rel_patent_doc_number] =>) 16/950449 | Antisense nucleic acids | Nov 16, 2020 | Issued |
Array
(
[id] => 16885759
[patent_doc_number] => 20210171954
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2021-06-10
[patent_title] => ANGIOPOIETIN-LIKE 3 (ANGPTL3) iRNA COMPOSITIONS AND METHODS OF USE THEREOF
[patent_app_type] => utility
[patent_app_number] => 17/089854
[patent_app_country] => US
[patent_app_date] => 2020-11-05
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 53248
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -23
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17089854
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/089854 | Angiopoietin-like 3 (ANGPTL3) iRNA compositions and methods of use thereof | Nov 4, 2020 | Issued |
Array
(
[id] => 18058346
[patent_doc_number] => 20220389432
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-08
[patent_title] => Allele-specific silencing therapy for DFNA9 using antisense oligonucleotides
[patent_app_type] => utility
[patent_app_number] => 17/772549
[patent_app_country] => US
[patent_app_date] => 2020-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 12109
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -13
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17772549
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/772549 | Allele-specific silencing therapy for DFNA9 using antisense oligonucleotides | Oct 28, 2020 | Pending |
Array
(
[id] => 18065705
[patent_doc_number] => 20220396792
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-12-15
[patent_title] => METHOD FOR PRODUCING NUCLEIC ACID MOLECULE, BIOMATERIAL, AND METHOD FOR PRODUCING BIOMATERIAL
[patent_app_type] => utility
[patent_app_number] => 17/773461
[patent_app_country] => US
[patent_app_date] => 2020-10-29
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 18038
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -8
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17773461
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/773461 | METHOD FOR PRODUCING NUCLEIC ACID MOLECULE, BIOMATERIAL, AND METHOD FOR PRODUCING BIOMATERIAL | Oct 28, 2020 | Pending |
Array
(
[id] => 17946096
[patent_doc_number] => 20220333113
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-10-20
[patent_title] => Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein
[patent_app_type] => utility
[patent_app_number] => 17/766013
[patent_app_country] => US
[patent_app_date] => 2020-10-15
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 14134
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -9
[patent_words_short_claim] => 17
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17766013
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/766013 | Nucleic Acid Compounds that Bind to Retinoic Acid-Inducible Gene I Protein | Oct 14, 2020 | Pending |
Array
(
[id] => 18020986
[patent_doc_number] => 20220372485
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2022-11-24
[patent_title] => APTAMER BASED SYSTEM TO QUANTIFY ANTI-THROMBIN III IN BLOOD
[patent_app_type] => utility
[patent_app_number] => 17/767349
[patent_app_country] => US
[patent_app_date] => 2020-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 8213
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -18
[patent_words_short_claim] => 65
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17767349
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/767349 | APTAMER BASED SYSTEM TO QUANTIFY ANTI-THROMBIN III IN BLOOD | Oct 13, 2020 | Pending |
Array
(
[id] => 18612661
[patent_doc_number] => 20230279393
[patent_country] => US
[patent_kind] => A1
[patent_issue_date] => 2023-09-07
[patent_title] => Treatment of Airway Conditions by Modulation of MiR200 Family MicroRNAs
[patent_app_type] => utility
[patent_app_number] => 17/769322
[patent_app_country] => US
[patent_app_date] => 2020-10-14
[patent_effective_date] => 0000-00-00
[patent_drawing_sheets_cnt] => 0
[patent_figures_cnt] => 0
[patent_no_of_words] => 11283
[patent_no_of_claims] => 0
[patent_no_of_ind_claims] => -15
[patent_words_short_claim] => 2
[patent_maintenance] => 1
[patent_no_of_assignments] => 0
[patent_current_assignee] =>[type] => publication
[pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 17769322
[rel_patent_id] =>[rel_patent_doc_number] =>) 17/769322 | Treatment of Airway Conditions by Modulation of MiR200 Family MicroRNAs | Oct 13, 2020 | Pending |